What Happened to GeneDx Holdings?
Ticker: WGSSPAC Year: 2020Merger: 2022
Return
+621.4%
Current Price
$72.14
Peak Price
$896.94
Trust Size
$524M
Summary
GeneDx is a leading genomic diagnostics company and the most widely used provider of whole exome and whole genome sequencing for rare and undiagnosed genetic conditions in children.
What Happened
GeneDx's public market journey began when Sema4 went public in July 2021 through a SPAC merger with CM Life Sciences (backed by Casdin Capital and Corvex Management). Sema4 then acquired GeneDx from BioReference Laboratories in 2022 and subsequently rebranded the entire company as GeneDx (ticker WGS). The company conducted a reverse stock split after the stock plummeted, but has since staged a remarkable comeback, with shares surging on strong demand for genetic testing and improving financials.
Timeline
2020-08-24
S-1 Registration Filed
2022-03-31
Merger Proxy Filed (DEFM14A)